Article (Scientific journals)
Normal and Pathological NRF2 Signalling in the Central Nervous System.
Heurtaux, Tony; Bouvier, David S; Benani, Alexandre et al.
2022In Antioxidants, 11 (8), p. 1426
Peer Reviewed verified by ORBi
 

Files


Full Text
antioxidants-11-01426.pdf
Author postprint (4.23 MB)
Download

All documents in ORBi are protected by a user license.

Send to



Details



Keywords :
NRF2; ageing; cancer; diet; epigenetic regulation; glial cells; neurodegeneration; reactive oxygen species; Food Science; Physiology; Biochemistry; Molecular Biology; Clinical Biochemistry; Cell Biology
Abstract :
[en] The nuclear factor erythroid 2-related factor 2 (NRF2) was originally described as a master regulator of antioxidant cellular response, but in the time since, numerous important biological functions linked to cell survival, cellular detoxification, metabolism, autophagy, proteostasis, inflammation, immunity, and differentiation have been attributed to this pleiotropic transcription factor that regulates hundreds of genes. After 40 years of in-depth research and key discoveries, NRF2 is now at the center of a vast regulatory network, revealing NRF2 signalling as increasingly complex. It is widely recognized that reactive oxygen species (ROS) play a key role in human physiological and pathological processes such as ageing, obesity, diabetes, cancer, and neurodegenerative diseases. The high oxygen consumption associated with high levels of free iron and oxidizable unsaturated lipids make the brain particularly vulnerable to oxidative stress. A good stability of NRF2 activity is thus crucial to maintain the redox balance and therefore brain homeostasis. In this review, we have gathered recent data about the contribution of the NRF2 pathway in the healthy brain as well as during metabolic diseases, cancer, ageing, and ageing-related neurodegenerative diseases. We also discuss promising therapeutic strategies and the need for better understanding of cell-type-specific functions of NRF2 in these different fields.
Disciplines :
Laboratory medicine & medical technology
Author, co-author :
Heurtaux, Tony ;  Department of Life Sciences and Medicine (DLSM), University of Luxembourg, 4367 Belvaux, Luxembourg ; Luxembourg Center of Neuropathology (LCNP), 3555 Dudelange, Luxembourg
Bouvier, David S ;  Luxembourg Center of Neuropathology (LCNP), 3555 Dudelange, Luxembourg ; National Center of Pathology (NCP), Laboratoire National de Santé (LNS), 3555 Dudelange, Luxembourg ; Luxembourg Centre of Systems Biomedicine (LCSB), University of Luxembourg, 4367 Belvaux, Luxembourg
Benani, Alexandre ;  Centre des Sciences du Goût et de l'Alimentation, AgroSup Dijon, CNRS, INRAE, Université Bourgogne Franche-Comté, 21000 Dijon, France
Helgueta Romero, Sergio  ;  Université de Liège - ULiège > GIGA > GIGA Neurosciences - Molecular Regulation of Neurogenesis ; Department of Life Sciences and Medicine (DLSM), University of Luxembourg, 4367 Belvaux, Luxembourg ; Luxembourg Center of Neuropathology (LCNP), 3555 Dudelange, Luxembourg
Frauenknecht, Katrin B M ;  Luxembourg Center of Neuropathology (LCNP), 3555 Dudelange, Luxembourg ; National Center of Pathology (NCP), Laboratoire National de Santé (LNS), 3555 Dudelange, Luxembourg
Mittelbronn, Michel;  Department of Life Sciences and Medicine (DLSM), University of Luxembourg, 4367 Belvaux, Luxembourg ; Luxembourg Center of Neuropathology (LCNP), 3555 Dudelange, Luxembourg ; National Center of Pathology (NCP), Laboratoire National de Santé (LNS), 3555 Dudelange, Luxembourg ; Luxembourg Centre of Systems Biomedicine (LCSB), University of Luxembourg, 4367 Belvaux, Luxembourg ; Luxembourg Institute of Health (LIH), 1526 Luxembourg, Luxembourg
Sinkkonen, Lasse ;  Department of Life Sciences and Medicine (DLSM), University of Luxembourg, 4367 Belvaux, Luxembourg
Language :
English
Title :
Normal and Pathological NRF2 Signalling in the Central Nervous System.
Publication date :
22 July 2022
Journal title :
Antioxidants
eISSN :
2076-3921
Publisher :
MDPI, Switzerland
Volume :
11
Issue :
8
Pages :
1426
Peer reviewed :
Peer Reviewed verified by ORBi
Funding text :
S.H.R. is supported by Fonds National de Recherche de Luxembourg (FNR)-PRIDE (PRIDE17/12244779/PARK-Q); L.S. has received funding from FNR, Fondation du Pélican de Mie et Pierre Hippert-Faber, Luxembourg Rotary Foundation, Luxembourg Personalized Medicine Consortium, and University of Luxembourg Internal Research Project grants; M.M. would like to thank the FNR for the support (PEARL P16/BM/11192868 grant).
Available on ORBi :
since 24 April 2024

Statistics


Number of views
3 (2 by ULiège)
Number of downloads
0 (0 by ULiège)

Scopus citations®
 
23
Scopus citations®
without self-citations
23
OpenCitations
 
13

Bibliography


Similar publications



Contact ORBi